ADVFN US – Market Content Editor
-
NEXT10 Binding LOI Targets Approximately 75% Ownership of BitFrontier Capital Holdings
NEXT10 (USOTC:NXTN) has signed a binding letter of intent with BitFrontier Capital Holdings (USOTC:BFCH), doing business as UNLOCKD, for a staged strategic transaction that could ultimately give NEXT10 approximately 75% ownership of BFCH. Key Investor Takeaways Why NXTN and BFCH Stocks Are in Focus NEXT10 has entered into a binding LOI with BFCH outlining a…
-
Sky Quarry Restarts Eagle Springs Refinery After Receiving Nevada Air Permit
Sky Quarry (NASDAQ:SKYQ) has restarted Nevada’s only crude oil refinery following regulatory approval and approximately $300,000 of repairs and upgrades, with the company now focused on ramping operations toward the facility’s 5,000-barrel-per-day nameplate capacity. Key Investor Takeaways Why SKYQ Stock Is in Focus Sky Quarry has restarted its Eagle Springs Refinery near Ely, Nevada, after…
-
Profusa ISO 13485 Certification Decision Advances Lumee Oxygen Platform Toward CE Mark
Profusa received a positive decision from GMED on ISO 13485 certification, expected in early October, while additional European MDR conformity assessment work remains before the Lumee Oxygen Platform can receive a CE mark. Key Investor Takeaways Why PFSA Stock Is in Focus Profusa has received a positive decision from GMED regarding ISO 13485 certification of…
-
aTyr Pharma FDA Alignment Sets Protocol for Phase 3 Efzofitimod Study in Pulmonary Sarcoidosis
aTyr Pharma plans to begin study-related activities in the fourth quarter of 2026 after reaching FDA alignment on a global Phase 3 efzofitimod trial, although further development will require additional capital. Key Investor Takeaways Why ATYR Stock Is in Focus aTyr Pharma has reached agreement with the FDA on the protocol for its planned Phase…
-
WTW AI Workforce Transformation Partnership With Softtek Targets Enterprise Implementation
WTW (NASDAQ:WTW) has partnered with Softtek to combine workforce strategy and organizational change expertise with AI engineering and implementation capabilities, targeting companies seeking to move AI transformation plans into operational deployment. Key Investor Takeaways Why WTW Stock Is in Focus WTW announced a strategic partnership with Softtek designed to help organizations implement AI-related workforce changes…
-
FirstService Residential EV Charging Program Participation Extends to Three Alexandria Communities
FirstService Residential-managed communities are participating in Alexandria’s EV charging initiative, giving three condominium communities access to technical support and potential reimbursement grants for charger installations. Key Investor Takeaways Why FSV Stock Is in Focus FirstService Residential said Marina Towers Condominium Association, Northampton Place Condominium and Parkfairfax Condominium have participated in the Plug in Alexandria program.…
-
Satellos Receives FDA Clearance to Study Forazapadin in FSHD
Satellos Bioscience Inc. (NASDAQ:MSLE) has received clearance from the U.S. Food and Drug Administration for its Investigational New Drug application to evaluate forazapadin in facioscapulohumeral muscular dystrophy, or FSHD, according to a company statement. The clearance allows Satellos to proceed with clinical testing of forazapadin in FSHD and represents the second clinical indication being investigated…
-
Vistagen Presents Fasedienol Subgroup Data in Severe Social Anxiety Disorder
Vistagen (NASDAQ:VTGN) presented exploratory clinical data for its investigational fasedienol nasal spray at Psych Congress 2026 in New Orleans on September 24, reporting findings from subgroup analyses involving participants with very severe social anxiety disorder. The findings were derived from two randomised, double-blind, placebo-controlled clinical trials and included one post-hoc analysis and one prespecified subgroup…
-
Cullinan Therapeutics Plans Q4 2026 Clinical Data Updates Across Three T Cell Engager Programs
Cullinan Therapeutics, Inc. (NASDAQ:CGEM) plans to report clinical data from three T cell engager programmes during the fourth quarter of 2026, covering candidates being evaluated in autoimmune diseases and acute myeloid leukaemia. The Cambridge, Massachusetts-based biopharmaceutical company expects to provide updates on velinotamig, CLN-978 and CLN-049 during November and December. The planned readouts involve investigational…
-
Acadia Pharmaceuticals Shares Fall After RADIANT Phase 2 Study Misses Primary Endpoint
Acadia Pharmaceuticals Inc. (NASDAQ:ACAD) shares fell 6% after the company reported results from its Phase 2 RADIANT study of remlifanserin in Alzheimer’s disease psychosis, with the trial missing its primary endpoint while meeting a key secondary measure at nominal statistical significance. The study evaluated 30 mg and 60 mg once-daily doses of remlifanserin against placebo.…